"Double-Blind Method" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.
| Descriptor ID |
D004311
|
| MeSH Number(s) |
E05.318.780.300 E05.581.500.300 N05.715.360.780.320 N06.850.520.445.300
|
| Concept/Terms |
Double-Blind Method- Double-Blind Method
- Double Blind Method
- Double-Blind Methods
- Method, Double-Blind
- Methods, Double-Blind
- Double-Masked Method
- Double Masked Method
- Double-Masked Methods
- Method, Double-Masked
- Methods, Double-Masked
- Double-Masked Study
- Double Masked Study
- Double-Masked Studies
- Studies, Double-Masked
- Study, Double-Masked
- Double-Blind Study
- Double Blind Study
- Double-Blind Studies
- Studies, Double-Blind
- Study, Double-Blind
|
Below are MeSH descriptors whose meaning is more general than "Double-Blind Method".
Below are MeSH descriptors whose meaning is more specific than "Double-Blind Method".
This graph shows the total number of publications written about "Double-Blind Method" by people in this website by year, and whether "Double-Blind Method" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 14 | 14 |
| 1997 | 0 | 28 | 28 |
| 1998 | 0 | 16 | 16 |
| 1999 | 0 | 23 | 23 |
| 2000 | 0 | 20 | 20 |
| 2001 | 0 | 20 | 20 |
| 2002 | 0 | 33 | 33 |
| 2003 | 0 | 30 | 30 |
| 2004 | 0 | 36 | 36 |
| 2005 | 0 | 39 | 39 |
| 2006 | 0 | 35 | 35 |
| 2007 | 0 | 33 | 33 |
| 2008 | 0 | 38 | 38 |
| 2009 | 0 | 53 | 53 |
| 2010 | 0 | 35 | 35 |
| 2011 | 0 | 57 | 57 |
| 2012 | 0 | 51 | 51 |
| 2013 | 0 | 51 | 51 |
| 2014 | 0 | 74 | 74 |
| 2015 | 0 | 58 | 58 |
| 2016 | 0 | 38 | 38 |
| 2017 | 0 | 61 | 61 |
| 2018 | 0 | 52 | 52 |
| 2019 | 0 | 48 | 48 |
| 2020 | 0 | 49 | 49 |
| 2021 | 0 | 51 | 51 |
| 2022 | 0 | 48 | 48 |
| 2023 | 0 | 36 | 36 |
| 2024 | 0 | 45 | 45 |
| 2025 | 0 | 55 | 55 |
| 2026 | 0 | 30 | 30 |
To return to the timeline,
click here.
Below are the most recent publications written about "Double-Blind Method" by people in Profiles.
-
Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial. Lancet Neurol. 2026 Aug; 25(8):721-730.
-
Losartan and prednisolone for post-COVID syndrome and cardiac inflammation: a randomized, double-blind, placebo-controlled trial. Nat Commun. 2026 07 30; 17(1).
-
Ensitrelvir for the Treatment of Hospitalized Adults With COVID-19: An International Phase 3 Randomized Placebo-controlled Trial. Clin Infect Dis. 2026 Jul 23; 83(1):59-69.
-
High-order brain interactions during ketamine-induced state changes: A functional marker of response in late-life treatment-resistant depression? Transl Psychiatry. 2026 Jul 04; 16(1).
-
Immune-Enhancing Nutrition and Outcomes After Radical Cystectomy: A Randomized Clinical Trial. JAMA Netw Open. 2026 Jul 01; 9(7):e2623622.
-
Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial. Lancet Gastroenterol Hepatol. 2026 Aug; 11(8):672-688.
-
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2026 Aug; 32(8):2948-2958.
-
Survodutide Once Weekly for the Treatment of Adults with Obesity. N Engl J Med. 2026 Aug 20; 395(8):776-787.
-
THRIVE: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of Veligrotug for Active Thyroid Eye Disease. Ophthalmology. 2026 Sep; 133(9):1085-1096.
-
A randomized, double-blind, controlled, parallel group study with amustaline/glutathione pathogen reduced red blood cells in regions at potential risk for Zika virus transfusion-transmitted infections (RedeS Study)-protocol for a phase 3 clinical trial. Trials. 2026 May 26; 27(1).